Title: | Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer |
Authors: | Ogiya, Akiko Browse this author |
Yamazaki, Kieko Browse this author |
Horii, Rie Browse this author →KAKEN DB |
Shien, Tadahiko Browse this author →KAKEN DB |
Horimoto, Yoshiya Browse this author |
Masuda, Norikazu Browse this author |
Inao, Touko Browse this author |
Hosoda, Mitsuchika Browse this author →KAKEN DB |
Ishida, Naoko Browse this author |
Osako, Tomofumi Browse this author |
Takahashi, Masato Browse this author |
Endo, Yumi Browse this author →KAKEN DB |
Miyoshi, Yuichiro Browse this author |
Yasojima, Hiroyuki Browse this author |
Tomioka, Nobumoto Browse this author |
Yamashita, Hiroko Browse this author →KAKEN DB |
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society Browse this author |
Keywords: | Breast cancer |
Post-relapse survival |
Prognosis |
Estrogen receptor-positive |
Endocrine therapy |
Issue Date: | May-2017 |
Publisher: | Springer |
Journal Title: | Breast cancer |
Volume: | 24 |
Issue: | 3 |
Start Page: | 473 |
End Page: | 482 |
Publisher DOI: | 10.1007/s12282-016-0730-3 |
PMID: | 27628678 |
Abstract: | Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer. |
Rights: | The final publication is available at link.springer.com |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/70047 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|